Diligence memo · auto-generated · as of July 2, 2026
Alphyn Biologics, Inc.
Alphyn Biologics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Alphyn Biologics, Inc. operates in Biotechnology, based in ANNAPOLIS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Alphyn Biologics, Inc. has raised $9.3M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.2M on 2024-03-28.
Most recent recorded round closed around 2024-03-28.
Valuation (modeled)modeled
Provath models Alphyn Biologics, Inc. at approximately $31M (range $5.6M–$71M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.69× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (69% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 4.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 55% of Biotechnology peers (4293 compared).
Modeled value ranks above 36% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.